syndromic neurometabolic disease with non-X-linked intellectual disability
ORPHA: 1820733 Treatments Available
Overview
human disease
Available Treatments (3)
| Drug | Form | Status | Countries | Lead Time |
|---|---|---|---|---|
| Vigabatrin Orphan | Oral tablet 500mg; Oral powder for solution 500mg sachets | FDA Approved, EMA Approved | 6 | 14d |
| Carnitine Orphan | Oral tablet 330mg; Oral solution 100mg/mL; IV injection 200mg/mL | FDA Approved, EMA Approved | 9 | 7d |
| Levetiracetam | Oral tablet 250mg, 500mg, 750mg, 1000mg; Oral solution 100mg/mL; IV infusion 500mg/5mL | FDA Approved, EMA Approved | 11 | 3d |
Classification & Codes
Orphanet Code
ORPHA:182073syndromic neurometabolic disease with non-X-linked intellectual disability
| Orphanet | ORPHA:182073 |
| Treatments | 3 drug(s) |
| Status | published |
Treatment Summary
Factual Authority
Last Updated3/20/2026
Clinical DataHPO · Orphanet
Drug DataFDA · EMA · CDSCO